Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1891 GSK3: A Novel Therapeutic Target in NETs?

Introduction: GSK3 is a serine/threonine-kinase that plays a critical role in cancer. In neuroendocrine tumours (NETs) GSK3 is regularly overactivated.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Nölting S

Authors: Weis C, Aristizabal Prada E, Maurer J, Spöttl G, Grossman A,

Keywords: GSK3-inhibition, neuroendocrine tumors, combination treatment,

#1869 Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors

Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Schrader J

Authors: Weissmann V, Benten D, Fahl M, Eggers C, Izbicki J,

Keywords: targeted therapies, mTOR,

#1641 Somatostatin Receptor Expression in Adrenocortical Carcinoma

Introduction: Adrenocortical carcinoma (ACC) is an uncommon neoplasm with an estimated annual incidence of 0.5-2 cases per million population. Surgery of the adrenal tumor is the major treatment. When complete tumor removal is not possible, or in case of recurrence, medical treatment with O,p’DDD(mitotane) is recommended. The treatment of ACC is currently based on the mitotane partial responses have been described in 19-34% of cases, and there are single reports of complete responses.The discovery of somatostatin (SST) and the identification of stable SST analogs with a longer half-life have raised new hopes for the treatment of endocrine tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Voronkova I, Gurevich L, Kazanceva I, Krivosheev A, Britvin T,

Keywords: Adrenocortical carcinoma, Somatostatin receptor, Immunohistochemistry,

#631 Genotype – Phenotype Correlations and Timing of Prophylactic Thyroidectomy in Patients with Familial Medullary Thyroid Carcinoma

Introduction: Recommendations on the timing of prophylactic thyroidectomy (PTTE) in patients with familial medullary carcinoma (FMTC) are based on classification of RET mutations into four risk levels (ATA 2009).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Podoba J

Authors: Podoba J, Podobová M, Grigerová M, Weismanová E, Závodná K,

Keywords: familial medullary carcinoma, prophylactic thyroidectomy, timing,